Literature DB >> 28795401

Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials.

Richard Simon1.   

Abstract

The successful development of new drugs with a companion diagnostic based on genomic alteration of an oncogene has led to rethinking of all phases on clinical development of cancer drugs. We critically review some of the new clinical trial designs for biomarker-based cancer drug development. We try to clarify the objectives of the new designs and examine completed trials using these designs to evaluate what has been learned about these designs.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Year:  2017        PMID: 28795401     DOI: 10.1002/cpt.814

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  20 in total

Review 1.  Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology.

Authors:  Mei-Yin C Polley; Ying Kuen Cheung
Journal:  JCO Precis Oncol       Date:  2019-10-24

2.  Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update.

Authors:  Rebecca S Slack Tidwell; S Andrew Peng; Minxing Chen; Diane D Liu; Ying Yuan; J Jack Lee
Journal:  Clin Trials       Date:  2019-08-26       Impact factor: 2.486

Review 3.  Clinical potential of mass spectrometry-based proteogenomics.

Authors:  Bing Zhang; Jeffrey R Whiteaker; Andrew N Hoofnagle; Geoffrey S Baird; Karin D Rodland; Amanda G Paulovich
Journal:  Nat Rev Clin Oncol       Date:  2019-04       Impact factor: 66.675

Review 4.  The future of clinical trials in urological oncology.

Authors:  Vikram M Narayan; Philipp Dahm
Journal:  Nat Rev Urol       Date:  2019-10-11       Impact factor: 14.432

Review 5.  Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia.

Authors:  Yash B Joshi; Gregory A Light
Journal:  Front Psychiatry       Date:  2018-11-19       Impact factor: 4.157

Review 6.  An Overview of Phase 2 Clinical Trial Designs.

Authors:  Pedro A Torres-Saavedra; Kathryn A Winter
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-08-04       Impact factor: 7.038

Review 7.  Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?

Authors:  Sarah A Holstein; Vera J Suman; Philip L McCarthy
Journal:  Curr Hematol Malig Rep       Date:  2019-02       Impact factor: 4.213

8.  Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy.

Authors:  Bushra Weidenbusch; Günther H S Richter; Marie Sophie Kesper; Monika Guggemoos; Katja Gall; Carolin Prexler; Ilya Kazantsev; Alexandra Sipol; Lars Lindner; Michaela Nathrath; Olaf Witt; Katja Specht; Frigga Beitinger; Carolin Knebel; Stuart Hosie; Rüdiger von Eisenhardt-Rothe; Wilko Weichert; Irene Teichert-von Luettichau; Stefan Burdach
Journal:  Oncotarget       Date:  2018-04-17

Review 9.  Arguing for Adaptive Clinical Trials in Sepsis.

Authors:  Victor B Talisa; Sachin Yende; Christopher W Seymour; Derek C Angus
Journal:  Front Immunol       Date:  2018-06-28       Impact factor: 7.561

10.  Master protocol trials in oncology: Review and new trial designs.

Authors:  Akihiro Hirakawa; Junichi Asano; Hiroyuki Sato; Satoshi Teramukai
Journal:  Contemp Clin Trials Commun       Date:  2018-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.